Abstract
Introduction School-aged autistic children commonly experience social communication and interaction challenges in their everyday lives. While international evidence suggests that social skills group training (SSGT) programmes can support autistic children, improving their psycho-social functioning, to date there is no standardised evidence-based SSGT tailored towards the needs of autistic children aged 8 to 12 years living in the Chinese Mainland. Therefore, the primary objective is to evaluate the feasibility and acceptability of a culturally adapted 16-session version of the social skills programme KONTAKT™ in Chinese autistic children. Additionally, preliminary efficacy and cost-effectiveness will be assessed to inform a future definitive trial.
Methods and analysis This study will employ a randomised, single-blinded, wait-list controlled feasibility design with 36 Chinese autistic children aged 8 to 12 years with Intelligence Quotient over 70 referred to the Child Development Behaviour Centre, in Guangzhou, China. Participants will be randomly assigned to either the immediate training group or the delayed training group stratified by sex. Feasibility will be assessed using quantitative and qualitative data obtained from the KONTAKT™ CHILD participants, their parents, and facilitators of the programme. Preliminary efficacy and cost-effectiveness are assessed via quantitative data obtained at five time points. The primary efficacy outcome is participants’ improvement in social skills as measured by the Contextual
Assessment of Social Skills (CASS). Other outcomes include parents’ and teachers’ reports of participants’ autistic traits and adaptive functioning, participants’ self-report and projective tests for self-assertiveness and psycho-social functioning, and parent reports on parental reflective functioning and perceived school support. Common process factors and their effects on outcomes will also be explored. Cost-effectiveness will consider both societal and healthcare perspectives.
Ethics and dissemination The current study protocol has been reviewed and ethics approval has been obtained from the Ethical Board Committee at the Third Affiliated Hospital of Sun Yat-sen University (II2023-119-01). The trial was pre-registered in Chinese Clinical Trials (ChiCTR2300072136) on 2023 June 05. The results of this trial will be actively disseminated through peer-reviewed publications and conference presentations. Any identifiable personal information will be anonymised to protect confidentiality.
Protocol version 2.0, 2024 July 31
Strengths and limitations of this study
Comprehensive assessment of diverse outcomes via multiple informants.
Systematic cultural adaptation using the Integrative Cultural Adaptation Framework (ICAF)
ensuring the appropriateness of the Chinese version of KONTAKT™.
Collect data on readiness for change, providing insights into “help-seeker” effects.
Limited generalisability due to a single study site, location-specific inclusion, and absence of an active comparator.
Given the absence of previous research examining the efficacy of SSGT programs in autistic children in the Chinese Mainland, this study is appropriately a feasibility study. As such, only the preliminary efficacy of KONTAKT™ with this population in a small sample will be examined. The small sample size will limit the power of the study in examining the effect of moderators on the study outcomes.
Competing Interest Statement
Part of this protocol was presented as a poster at the International Society of Autism Research Annual Meeting, 2024 May 16. ZX received funding from the Guangdong Science and Technology Department, and ZH received funding from the Guangzhou Municipal Science and Technology Bureau. The funding organisations do not influence the study design, data collection/analysis/interpretation, manuscript review/approval, or publication decision. All other authors declare that they have no conflicts of interest.
Clinical Trial
ChiCTR2300072136
Clinical Protocols
https://www.chictr.org.cn/showproj.html?proj=195469
Funding Statement
This research now receives fundings from Guangdong Science and Technology Program (2023A1111120012) and Guangzhou Science and Technology Program (2024B03J0529).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethical Board Committee of the Third Affiliated Hospital of Sun Yat-sen University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
1.The analysis plan has been revisited, simplifying the regression models for preliminary efficacy outcomes and examining potential moderators of effects in an exploratory manner. 2.Emphasis has been placed on feasibility outcomes, with further details including the success criteria for certain feasibility parameters and the analysis plan outlined in the main manuscript. 3.Since the statistical methods of the current study protocol have been updated, the protocol version has been updated into v2.0, 2024 July 31. The updated protocol has been reviewed by the ethics committee and updated in the Chinese Clinical Trial Registry. 4. Include a supplementary table for a comparison between the KONTAKT CHILD programme and the Mandarin version of the PEERS, to facilitate a better understanding of their similarities and differences.
Data Availability
The ethical consent and funding documents have been reviewed by the review board of the Chinese Clinical Trial Registry and are available for review by the Editorial Office. Anonymised data related to this study will be available from the corresponding author upon reasonable request after study completion and publication of the study. The final dataset generated during this study will upload to the Research Data Deposit of Sun Yat-sen University. Trial results will be reported and published in scientific journals.
